

References

References

- Abeloff, Martin.** Manifestations of acute and chronic leukemias. *Clinical Oncology*. 2004; 2824-2827.
- Alexander D, Ichikawa H, Bechberger J, et al.** Normal cells control the growth of neighboring transformed cells independent of gap junction communication and Src activity. *Cancer Res*. 2004; 64: 1347.
- Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman JW, Porwit A, Thiele J and Bloomfield CD.** Acute myeloid leukemia with recurrent genetic abnormalities. In: *WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues*. 4th edition. Swerdlow SH, Campo E, Harris NL et al. (Eds.). International Agency for Research on Cancer (IARC), Lyon, France, 2008a; 110-123.
- Arber DA, Brunning RD, Orazi A, Bain BJ, Porwit A, Vardiman JW, Le Beau MM and Greenberg PL.** Acute myeloid leukemia with myelodysplasia-related changes. In: *WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues*. 4th edition. Swerdlow SH, Campo E, Harris NL et al. (Eds.). International Agency for Research on Cancer (IARC), Lyon, France, 2008b; 124-126.
- Ayoubi TA, Van D and Ven WJ.** Regulation of gene expression by alternative promoters. *FASEB Journal*. 1996; 10: 453-460.
- Bain BJ.** Leukemia Diagnosis, 3rd eds. Blackwell Publishing, Oxford, 2001; 97-101.
- Bain BJ.** Acute leukemia: Immunophenotypic, cytogenetic and molecular genetic analysis in the classification of acute leukemia- The EGIL, MIC, MIC-M and WHO classification. In: *leukemia Diagnosis*. 2003; 2:76.
- Bain BJ.** Diagnosis and classification of acute leukemia in Postgraduate Hematology. By: Hoffbrand AV, Catovsky D and Tuddenham EG (Eds.). 5th ed. 2005; 476-491.
- Basso G, Lanza F, Orfao A, et al.** Clinical and biological significance of CD34 expression in acute leukemia. *Journal of Biological Regulators and Homeostatic Agents*. 2001; 15: 68.

- Bauer N, Fonseca AV, Florek M, Freund D, Jasza J, Bornhauser M, Fargeas CA and Corbeil D.** New insights into the cell biology of hematopoietic progenitors by studying prominin-1 (CD133). *Cells Tissues Organs*. 2008; 188(1-2): 127-138.
- Bereshchenko O, Mancini E, Moore S, Bilbao D, Mansson R, Luc S, Grover A, Jacobsen SE, Bryder D and Nerlov C.** Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML. *Cancer Cell*. 2009; 16(5): 390-400.
- Berndt MC, Shen Y and Depheide SM.** The vascular biology of the glycoprotein 1b-1X-V. *Thromb Haemostat*. 2001; 86: 178.
- Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabrò E, Pastorino U and Sozzi G.** Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. *Proc Natl Acad Sci U S A*. 2009; 106(38): 16281-6.
- Bidlingmaier S, Zhu X and Liu B.** The utility and limitation of glycosylated human CD133 epitopes in defining cancer stem cells. *J Mol Med*. 2008; 86: 1025-1032.
- Bissels U, Wild S, Tomiuk S, Hafner M, Scheel H, Mihailovic A, Choi YH, Tuschl T and Bosio A.** Combined Characterization of MicroRNA and mRNA Profiles Delineates Early Differentiation Pathways of CD133 (+) and CD34 (+) Hematopoietic Stem and Progenitor Cells Stem Cells. 2011; 10: 627.
- Boice J and Inskip P.** Radiation induced leukemia. In: Henderson E and Lister T (Eds.). In: *Leukemia*. 6th ed. WB Saunders, Company Philadelphia. 1996; 195.
- Boivin D, Labbe D, Fontainbe N, Lamy S, Beaulieu E, Gingras D and Belivean R.** The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases. *Biochemistry*. 2009; 48(18): 3998-4007.
- Braham J, Omri H, Senana S, Fekih S, Hizem S, Sriha B, Khelif A, Saad A and Kortas M.** Identification of the translocation t(15; 17) in acute myeloid leukemia

initially classified as FAB M₁: case report and review of the literature. Clin Lab. 2006; 3: 125.

Breems DA and Löwenberg B. Acute myeloid leukemia and the position of autologous stem cell transplantation. Semin Hematol. 2007; 44(4): 259.

Brown M and Wittwer C. Flow cytometry: principles and clinical applications in hematology. Clinical Chemistry. 2000; 46: 1221.

Brunning RD, Matutes E and Harris NL, et al. Acute myeloid leukemia. In: World Health Organization Classification of Tumors Pathology and Genetics: tumors of hematopoietic and lymphoid tissues. By: Jaffe ES, Harris NL, Stein H and Vardiman JW (Eds.); Lyon; IARC Press. 2001; 75.

Bruno S, Bussolati B, Grange C, et al. CD133 positive renal progenitor cells contribute to tumor angiogenesis. American Journal of Pathology. 2006; 169: 2223.

Buhring HJ, Seiffert M, Marxer A et al. AC133 antigen expression is not restricted to acute myeloid leukemia but is also found on acute lymphoid leukemia blasts and on a subset of CD34⁺ B-cell precursors. Blood. , 2002; 94:832-3.

Buonamici S, Ottoviani E, Testoni N, et al. Real-time quantitation of minimal residual disease in inv (16)- positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood. 2002; 99: 443.

Byrd JC, Mrozek K and Dodge PK. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse and overall survival in adult patients. Blood. 2002; 100: 4325-4336.

Campidelli C, Agostinelli C, Stitson R and Pileri SA. Myeloid sarcoma: extramedullary manifestation of myeloid disorders. Am J Clin Pathol. 2009; 132(3): 426-437.

Campos B and Herold-Mende CC. Insight into the complex regulation of CD133 in glioma. J Cancer. 2011; 128(3): 501-10.

Castoldi G, Sofritti O, Fraulini C, et al. Neoplastic circulating endothelial-like cells in patients with acute myeloid leukemia. Eur J Haematol. 2007; 78(5): 365.

- Catovsky D and Hoffbrand AV.** Acute leukemia. In: Post Graduate Hematology. By: Hoffbrand, A.V., 4th edition; Oxford Boston; Butterworth Heinemann. 1999; 18: 298.
- Charrier S, Boiret N, Fouassier M, et al.** Normal human bone marrow CD34 positive CD133 positive cells contain primitive cells able to produce different categories of colony-forming unit megakaryocytes in vitro. *Exp Hematol.* 2002; 30(9): 1051.
- Cheson BD, Bennett JM, Kopecky KJ, et al.** Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. *J Clin Oncol.* 2003; 21: 4642.
- Christian W, Richard R, Gunther S, Claudia S, Jochen H, Susanne S, Torsten H, Ursula C, Christian S, Leonid K and Wolf-Dieter L.** Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping. *Haematologica.* 2001; 86:154-161.
- Corbeil D, Roper K, Fargeas A, et al.** Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. *Traffic.* 2001; 2: 82.
- Corbeil D, Roper K, Hellwig A et al.** The human CD133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. *J Biol Chem.* 2003; 275:5512-20.
- D'Alessio F, Mirabelli P, Gorrese M, Scalia G, Gemei M, Mariotti E, Di Noto R, Martinelli P, Fortunato G, Paladini D and Del Vecchio L.** Polychromatic flow cytometry analysis of CD34+ hematopoietic stem cells in cryopreserved early preterm human cord blood samples. *Cytometry A.* 2011; 79(1): 14-24.
- De Sanctis V, Mazzucconi MG, Spadea A, et al.** Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukemic evolution. *Br J Haematol.* 2003; 123: 517.
- Del Poeta G, Venditti A, Del Principe MI, et al.** Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML).

Blood. 2003; 101(6): 2125.

Dohner K and Dohner H. Molecular characterization of acute myeloid leukemia. *Haematologica*. 2008; 93(7): 976-82.

Dong F, Dale D and Bonilla M. Mutations in the granulocyte colony stimulating factor receptor gene in patients with severe congenital neutropenia. *Leukemia*. 1997; 11: 120.

Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland MC, Berdel WE, Buchner T, Wormann B, Braess J, Hiddemann W, Bohlander SK and Spiekermann K. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. *J Clin Oncol*. 2010; 28(4): 570-577.

Dunna NR, Rajappa S, Digumarti R, Vure S, Kagita S, Damineni S, Rao VR, Yadav SK, Ravuri RR and Satti V. Fms Like Tyrosine Kinase (FLT3) and Nucleophosmin 1 (NPM1) Mutations in De Novo Normal Karyotype Acute Myeloid Leukemia (AML). *Asian Pac J Cancer Prev*. 2010; 11(6): 1811-6.

Facchetti F, Jones D and Petrella T. Blastic plasmacytoid dendritic cell neoplasm. In: *WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues*. 4th edition. Swerdlow SH, Campo E, Harris NL et al. (Eds.). International Agency for Research on Cancer (IARC), Lyon, France, 2008; 145-147.

Facchetti F, Pileri SA, Agostinelli C, Martelli MP and Paulli M. Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm. *Hematologica*. 2009; 94 (2): 285-288.

Falini B, Lenze D, Hasserjian R, Coupland S, Jaehne D, Soupir C, Liso A, Martelli MP, Bolli N, Bacci F, Pettirossi V, Santucci A, Martelli MF, Pileri S and Stein H. Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. *Leukemia*. 2007a; 21(7): 1566-1570.

Falini B, Maciejewski K, Weiss T, Bacher U, Schnittger S, Kern W, Kohlmann A, Klein Hu, Vignetti M, Piciocchi A, Fazi P, Martelli MP, Vitale A, Pileri S,

- Miesner M, Santucci A, Haferlach C, Mandelli F and Haferlach T.** Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). *Blood*. 2010; 115(18): 3776-3786.
- Falini B, Mecucci C, Tiacci E, et al.** Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. *N Engl J Med*. 2005; 352: 254.
- Falini B, Tiacci E, Martelli MP, Ascani S and Pileri SA.** New classification of acute myeloid leukemia and precursor-related neoplasms: changes and unsolved issues. *Discov Med*. 2010; 10(53): 281-92.
- Fargeas C, Florek M, Huttner WB and Corbeil D.** Characterization of prominin-2, a new member of the prominin family of pentaspan membrane glycoproteins. *Journal of Biological Chemistry*. 2003; 278(10): 8586-8596.
- Fargeas CA, Fonseca AV, Huttner WB and Corbeil D.** Prominin-1 (CD133) from progenitor cells to human diseases. *Future Lipidology*. 2006; 1: 213-225.
- Fauth F, Weidmann E, Martin H, et al.** AC133 expression on acute myeloid leukemia blasts: association to FAB and to CD34 expression and possible implications for peripheral blood progenitor cell purging in AML. *Leuk Res*. 2001; 3: 191.
- Feller N, Pol M, Waaijman T, et al.** Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients. *Clinical Cancer Research*. 2005; 11: 4793.
- Flombaum C.** Metabolic emergencies in the cancer patient. *Semin Oncol* 2000; 3: 332.
- Florek M, Haase M, Marzesco AM, Freund D, Ehninger G, Huttner WB and Corbeil D.** Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. *Cell Tissue Res*. 2005; 319(1): 15-26.
- Gaiser T, Camps J, Meinhardt S, Wangsa D, Nguyen QT, Varma S, Dittfeld C, Kunz-Schughart LA, Kemmerling R, Becker MR, Heselmeyer-Haddad K and Ried T.** Genome and Transcriptome Profiles of CD133-Positive Colorectal Cancer

Cells. Am J Pathol. 2011; 178(4): 1478-88.

Gallacher L, Murdoch B, Wu DM et al. Isolation and characterization of human CD34⁺ Lin⁻ and CD34⁺ Lin⁻ hematopoietic stem cell using cell surface markers CD133 and CD7. Blood. 2003; 95: 2813-20.

Giebel B, Corbeil D, Beckmann J, et al. Segregation of lipid raft markers including CD133 in polarized human hematopoietic stem and progenitor cells. Blood. 2004; 104: 2332.

Golub TR and Arceci RJ. Acute myelogenous leukemia. In: Principles and Practice of Pediatric Oncology. By: Pizzo P and Poplack D. (Eds), Philadelphia: Lippincott Williams & Wilkins. 2002; 545.

Gorczyca W. Clinical and laboratory parameters. In: Prognostic Markers in Hematologic Oncology; London and New York; Taylor and Francis Group. 2006; 1: 11.

Gorczyca, W. Cytogenetic and molecular features in AML. In: Prognostic Markers in Hematologic Oncology; London and New York; Taylor and Francis Group. 2006; 8: 215.

Gowans I, Lorimore S, Mellrath J and Wright E. Genotype-dependent induction of transmissible chromosomal instability by gamma-radiation and the benzene metabolite hydroquinone. Cancer Res. 2005; 9: 3527.

Green CL, Koo KK, Hills RK, Burnett AK, Linch DC and Gale RE. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol. 2010; 28(16): 2739-2747.

Greer J, Baer M and Kinney M. Acute myelogenous leukemia. In: Wintrobe's Clinical Hematology. 10th ed., by: Lee GR, Foerster J and Luken J (eds.), Williams & Wilkins (A Waverly Company). Baltimore. 1999; 2272-80.

Greer J, Baer M and Kinney M. Acute myeloid leukemia in adults. In: Wintrobe's Clinical Hematology. By: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F and Glader B. (eds); 11th edition; Lippincott Williams & Wilkins. 2004; 1713.

- Guenova M and Balatzenko G.** CD133-2 (AC141) expression analysis in acute leukemia immunophenotyping in correlation to CD34 and P-glycoprotein. *Hematology*. 2008; 13(3):137-141.
- Guinn B, Mohamedali A, Mills K, et al.** Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemia. *Biomarker Insights*. 2007; 2: 1.
- Haferlach T, Schoch C, Löffler H, et al.** Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. *J Clin Oncol*. 2003; 21(15): 256.
- Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K and Barnard GF.** Characterization of a side population of cancer cells from human gastrointestinal system. *Stem Cells*. 2006; 24: 506-513.
- Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DK, Wheatley K, De Graaf SS, Van Den Berg E, Burnett AK and Gibson BE.** Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. *J Clin Oncol*. 2010; 28(16): 2674-2681.
- Haruchika M and Asahara T.** Post-natal endothelial progenitor cells for neovascularization in tissue regeneration. *Cardiovascular Research*. 2003; 58(2): 390.
- Hassan H and Zander A.** stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis. *Acta Hematol*. 1996; 95: 257.
- Head D.** Classification and Differentiation of Acute Leukemias. In: *Wintrobe's Clinical Hematology*. By: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F and Glader B. (eds), 11th edition; USA; Lippincott Williams & Wilkins (publishers). 2004; 1687.
- Hemmoranta H, Hautaniemi S, Niemi J, Nicorici D, Laine J, Yli-Harja O, Partanen**

- J and Jaatinen T.** Transcriptional profiling reflects shared and unique characters for CD34+ and CD133+ cells. *Stem Cells Dev.* 2006; 15(6): 839-51.
- Hermansen SK, Christensen KG, Jensen SS and Kristensen BW.** Inconsistent Immunohistochemical Expression Patterns of Four Different CD133 Antibody Clones in Glioblastoma. *J Histochem Cytochem.* 2011; 59(4): 391-407.
- Hess D, Wirthlin L, Craft T, et al.** Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. *Blood.* 2006; 107(5): 2162.
- Hoffbrand AV, Moss PAH and Pettit JE.** Acute leukemias. In: *Essential Hematology*, 5th edition. USA, Blackwell Publishing. 2006; 157.
- Horn PA, Tesch H and Staib P.** Expression of CD133, a novel hematopoietic precursor antigen, on acute myeloid leukemia cell line. *Blood.* 1999; 93: 1435-7.
- Hughes WT, Armstrong D and Bodey GP.** Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. *Clinical Infectious Diseases.* 2002; 34: 730-33.
- Immervoll H, Hoem D, Sakariassen PO, Steffenson OJ and Molven A.** Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. *BMC Cancer.* 2008; 8: 48.
- Isidori A, Motta MR, Tani M, et al.** Positive selection and transplantation of autologous highly purified CD133 positive stem cells in resistant/relapsed chronic lymphocytic leukemia patients' results in rapid hematopoietic reconstitution without an adequate leukemic cell purging. *Biol Blood Marrow Transplant.* 2007; 10: 1224.
- Jaatinen T, Hemmoranta H, Hautaniemi S, et al.** Global gene expression profile of human cord blood-derived CD133 positive cells. *Stem cells.* 2006; 24 (3): 631.
- Jaffe ES, Harris NL, Stein H, et al.** *World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues.* Lyon, France: IARC Press. 2001: 14.
- Jászai J, Janich P, Farkas L, et al.** Differential expression of Prominin-1 (CD133) and

Prominin-2 in major cephalic exocrine glands of adult mice. *Histochemistry and Cell Biology*. 2007; 128(5): 409.

Jegalian AG, Buxbaum NP, Facchetti F, Raffeld M, Pittaluga S, Wayne AS and Jaffe ES. Blastic plasmacytoid dendritic cell neoplasm in the pediatric population: diagnostic features and clinical implications. *Haematologica*. 2009b.

Jegalian AG, Facchetti F and Jaffe ES. Plasmacytoid dendritic cells: physiologic roles and pathologic states. *Adv Anat Pathol*. 2009a; 16(6): 392-404.

Kaleem Z, Crawford E, Pathan MH, et al. Flow cytometric analysis of acute leukemias, diagnostic utility and critical analysis of data. *Arch Pathol*. 2003; 127: 42.

Kamprad M, Kindler S, Schuetze N and Emmrich F. Flow cytometric immunophenotyping of umbilical Cord and peripheral blood haematopoietic progenitor cells by different CD34 epitopes, CD133, P-Glycoprotein expression and Rhodamine-123 efflux. *Transfusion Med Hemotherapy*. 2007; 34: 195-203.

Kania G, Corbeil D, Fuchs J et al. Somatic stem cell marker prominin-1/CD133 is expressed in embryonic stem cell-derived progenitors. *Stem Cells*. 2005; 23(6): 791.

Karbanova J, Missol-Kolka E, Fonseca AV, Lorra C, Janich P, Hollerova H, Jaszai J, Ehrmann J, Kolar Z, Liebers C, Arl S, Subrtova D, Freund D, Mokry J, Huttner WB and Corbeil D. The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. *J. Histochem. Cytochem*. 2008; 56(11): 977-993.

Katoh Y and Katoh M. Comparative geneomics on PROM1 gene encoding stem cell marker CD133 *International Journal of molecular medicine*. 2007; 19: 967-970.

Keren A, Shafir O, Shimshoni E, Marvaud V, Bachschmidt A and Long J. Experimental estimates of dephasing time in molecular magnets. *Phys Rev Lett*. 2007; 98: 25-30.

Kerr JR, Barah F, Cunniffe VS, et al. Association of acute parvovirus B19 infection with new onset of acute lymphoblastic and myeloblastic leukemia. *J Clin Pathol*.

2003; 56: 873.

- Khawaja MR, Allana SS, Akbarali AN, Adil SN, Khurshid M and Pervez S.** Flow cytometric and demographic analysis of T cell acute lymphoblastic leukemia in Pakistani population. *J Ayub Med Coll Abbottabad*. 2005; 17(4): 1-6.
- Kim DH, Lee NY, Lee MH, et al.** Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukemia patients. *Br J Haematol*. 2008; 140(1): 71.
- Kim JH, Cho HI, Kim EC, Ko EK, See CJ, Park SY and Less DS.** A study on 289 consecutive Korean patients with acute leukaemias revealed fluorescence in situ hybridization detects the MLL translocation without cytogenetic initially and during follow-up. *Br J Haematol*. 2002; 119 (4): 930-939.
- Kinney MC and Lukens JN.** Classification and differentiation of acute leukemias. In: *Wintrobe's Clinical Hematology*. By: Lee GR, Forester J and Lukens JN. (eds); 10th edition; Baltimore; Williams & Wilkins (A Waverly Company). 2001; 2209.
- Kouroukis CT, Chia S, Verma S and Robson D.** Canadian supportive care recommendations for neutropenia in patients with cancer. *Curr Oncol*. 2008; 15(1): 9-3.
- Kratz-Albers K, Zuhlsdorf M, Leo R et al.** Expression of CD133, a novel stem cell marker, on human leukemic blasts CD34⁻ antigen and on human CD34⁺ leukemic cell line: MUTZ-2. *Blood*. 2001; 92:4485-7.
- Krause DS, Fackler MJ, Civin CI and May WS.** CD34: structure, biology and clinical utility. *Blood*. 1998; 87:1-13.
- Kudo K, Hama A, Kojima S, Ishii R, Morimoto A, Bessho F, Sunami S, Kobayashi N, Kinoshita A, Okimoto Y, Tawa A and Tsukimoto I.** Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy. *Int J Hematol*. 2010; 91(4): 630-635.
- Kumar Vinay, Abul Abbas and Fauslo N.** Robbins and Cortan pathologic basis of disease. 7th ed. 2004; 81: 8417-528.
- Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Sakura T, Kanamori H, et al.**

Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse. *Haematologica*. 2010; 95(11): 1857-64.

LaBarge, M. and Bissell, M. Is CD133 a marker of metastatic colon cancer stem cells? *J Clin Invest*. 2008; 118(6): 2021.

Larsson SC and Wolk A. Overweight and obesity and incidence of leukemia: a meta-analysis of cohort studies. *Int J Cancer*. 2008; 122(6): 1418.

Lee M, Tan T and Feng A. Clinicopathologic analysis of acute myeloid leukemia in a single institution: biphenotypic acute myeloid leukemia may not be an aggressive subtype. *Journal of the Chinese Medical Association*. 2007; 70(7): 269.

Lee ST, Ko YW, Hahn JS, et al. AC133 antigen as a prognostic factor in acute leukemia. *Leuk Res*. 2001; 25(9): 757.

Lichtman M and Brennan J. Myelodysplastic disorders (Indolent clonal myeloid diseases and oligoblastic leukemia). In: Beutler E, Lichtman M, Collier B and Kipps T (eds). In: *William's Hematology*. 6th ed. McGraw-Hill Companies, USA. 2001; 1029.

Lichtman MA and Liesveld JL. Acute myelogenous leukemia. In: *William's Hematology*. By: Beutler E, Lichtman MA, Collier BS, Kipps TJ and Seligsohn U. (eds); 6th edition; USA; McGraw-Hill companies. 2001; 780.

Lichtman MA and Liesveld JL. Acute Myelogenous leukemia. In: *William's Hematology*. BY: Lichtman MA, Kipps TJ, Kaushansky K, Beutler E, Seligsohn U and Prchal J. (eds); 7th edition; USA; McGraw-Hill companies. 2006; 1183.

Lin P and Medeiros LJ. Molecular genetic abnormalities. In: acute and chronic leukemias in *Molecular Diagnostics*, 2nd ed. By: Coleman WB and Tsongalis GJ (eds). University of Chicago Press. 2005; 415-435.

Lowenberg B, Griffin JD and Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. *Hematology*. 2003; 82:101.

Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L and Zlobec I. Prognostic impact of the expression of putative

cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. *Br J Cancer*. 2010; 103(3): 382-90.

Lugthart S, Groschel S, Beverloo HB, Kayser S, Valk PJ, Van Zelderen-Bhola SL, Jan Ossenkuppele G, Vellenga E, Van Den Berg-De Ruiters E, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Kohne CH, Pfreundschuh M, Horst HA, Koller E, Von Lilienfeld-Toal M, Bentz M, Ganser A, et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. *J Clin Oncol*. 2010; 28(24): 3890-3898.

Mahmoud L, Shamaa S, Salem M, Aladle D and Goda E. A study for evaluation of different diagnostic approaches in acute myeloid leukemia in Egypt. *Hematology*. 2006; 2: 87.

Marcucci G, Caligiuri MA and Bloomfield CD. Core binding factor (CBF) in acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically? *Eur J Haematol*. 2003; 71(3): 143.

Matutes E, Morrilla R and Catovsky D. Immunophenotyping. In: *Dacie and Lewis practical hematology*. By: Lewis, S.M.; Bain, B.J. and Bates, I.. (eds), 10th edition; USA; Churchill Livingstone Elsevier. 2006; 335.

Maw A, Corbeil D, Koch J, et al. A frameshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. *Hum Mol Genet*. 2000; 9: 27.

McCoy JP. Basic principles of flow cytometry. *Hematol Oncol Clin North Am*. 2002; 16: 229-243.

McKenna RW. Multifaceted approach to the diagnosis and classification of acute leukemias. *Clinical Chemistry*. 2000; 46: 1252-1259.

Mehra N, Penning M, Maas J, et al. Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. *Clinical Cancer Research*. 2006; 12: 4859.

- Melo M, Ahmed N, Lima C, Pagnano K, Bordin S, Lorand M, Saad S and Costa F.** Mutations in the P53 gene in acute myeloid leukemia patients correlate with poor prognosis. *Hematology*. 2002; 1: 13.
- Miller KB and Daoust PR.** Clinical manifestation of acute myeloid leukemia. In: *Hematology Basic Principles and Practice*. By: Hoffman R, Benz EJ, Shatil SJ, Furie B, Cohen HJ, Silberstien LE and McGlave P. (eds); 3rd edition; New York; Churchill Livingstone. 2000; 999.
- Miller KB and Daoust PR.** Clinical manifestation of acute myeloid leukemia. In: *Hematology Basic Principles and Practice*. By: Hoffman R, Benz EJ, Shatil SJ, Furie B, Cohen HJ, Silberstien LE and McGlave P. (eds); 4th edition; New York; Churchill Livingstone. 2005; 1125.
- Miraglia S, Godfrey W, Yin H, et al.** A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. *Blood*. 1997; 90: 5013.
- Mizrak D, Brittan M and Alison M.** CD133: molecule of the moment. *J Pathol*. 2008; 214(1): 3.
- Mughal T, Goldman J and Mughal S.** Different types of leukemias, lymphomas and myeloma. In: *Understanding Leukemias, Lymphomas and Myelomas*. London and New York; Taylor and Francis Group. 2006; 47.
- Neuroscience N.** Fluorescence in situ hybridization. *Nature Methods*. 2005; 2: 237-238
- O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, Foran JM, Goorha S, Maness LJ, Marcucci G, Maslak P, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS and Wang ES.** Acute myeloid leukemia. *J Natl Compr Canc Netw*. 2011 ; 9(3): 280-317.
- Okamoto O, Carvalho A, Marti L, et al.** Common molecular pathways involved in human CD133/CD34 positive progenitor cell expansion and cancer. *Cancer Cell International*. 2007; 7: 11.

- Orazi A.** Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/ myeloproliferative Diseases. Pathobiology. 2007; 74: 97.
- Orfao A, Schmitz G, Brando B, Ruiz-Arguelles A, Basso G, Braylan R, Lacombe F, Rothe G, Lanza F, Papa S, Lucio P, San Miguel J.** Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future direction. Clinical Chemistry. 1999; 45: 1708-1717.
- Paraskevas F.** Clusters of differentiation. In: Wintrobe's Clinical Hematology. By: Greer J, Foerster J, Lukens J, Rodgers G, Paraskevas F and Glader B. (eds); 11th edition; USA; Lippincott Williams and Wilkins Publishers. 2004; 79.
- Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, Bullinger L, et al.** IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication. J Clin Oncol. 2010; 28(22): 3636-43.
- Perrella G, Brusini P, Spelat R, et al.** Expression of haematopoietic stem cell markers, CD133 and CD34 on human corneal keratocytes. British Journal of Ophthalmology. 2007; 91: 94.
- Principe MI, Del Poeta G, Venditti A, et al.** Apoptosis and immaturity in acute myeloid leukemia. Hematology 2005; 10(1): 25.
- Provan D, Singer CJ, Baglin T and Lilleyman J.** Leukemia. In: Oxford Handbook of Clinical Hematology, 2nd edition. London, Oxford University Press. 2004; 149.
- Radcliff G and Jaroszeki MJ.** Basics of flow cytometry. In: Methods in molecular biology, flow cytometry protocols. By: Jaroszeki, MJ. and Heller, R. (eds), Totowa, New Jersey, Human Press Inc. 1998; 1.
- Ramos HV, Simoes, Mde J, Pontes PA, Neves LR, Barbosa LH, De Biase NG and Oshima CT.** Immunohistochemistry as a method to study elastic fibers of human

vocal fold. *Rev Bras Otorrinolaringol (Engl Ed)*. 2005; 71(4): 486-91.

Ramos-Vara JA. Technical aspects of immunohistochemistry. *Vet Pathol*. 2005; 42: 405.

Rappa G, Fodstad O and Lorico A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular Therapeutic Target for Metastatic Melanoma. *Stem Cells*. 2008; 26(12): 3008-3017.

Rebecca L, Brandt S and Brandt SJ. Molecular Biology and Hematology. In: *Wintrobe's Clinical Hematology*; By: Greer, J.; Foerster, J.; Lukens, J.; Rodgers, G.; Paraskevas, F. and Glader, B.(eds); 11th edition; USA; Lippincott Williams and Wilkins publishers. 2004; 131.

Redelman D. Flow cytometric analyses of cell phenotypes. In: *Immunophenotyping*. By: Stewart, C.C. and Nicholson J.K.A, (eds); New York, Wiley-Liss. 2000; 49.

Reynolds P, Von Behren J, Elkin EP, et al. Birth characteristics and leukemia in young children. *Am J Epidemiol*. 2002; 155: 603.

Rhenen A, Feller N, Kelder A, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. *Clin Cancer Res*. 2005; 11: 6520.

Romeo MJ, Wunderlich J, Ngo L, et al. Measuring tissue-based biomarkers by immunochromatography coupled with reverse-phase lysate microarray. *Clin Cancer Res*. 2006; 12(8): 2463.

Rowley JD. Molecular genetics in acute leukemia. *Leukemia*. 2000; 14: 513-517.

Russell NH. Biology of acute leukemia. *Lancet*. 1999; 349:118-22.

Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Kawamoto A, Yasuda H, Morimoto Y, Fujikawa H, Inoue Y, Miki C and Kusunoki M. Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer. *Oncol Rep*. 2010; 24(2): 345-50.

Sanz MA. Treatment of Acute Promyelocytic Leukemia. *Hematology Am Soc Hematol*

Educ program. 2006; 147.

Saxena R and Anand H. Flow cytometry in acute leukemia. Indian J Hematol & Blood Transfus. 2008; 24 (4): 146-150.

Schlenk RF, Benner A, Hartmann F, Del Valle F, Weber C, Pralle H, Fischer JT, Gunzer U, Pezzutto A, Weber W, Grimminger W, Preiss J, Hensel M, Fröhling S, Döhner K, Haas R and Döhner H. Risk-adapted post-remission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia. 2003; 17(8):1521-8.

Schlenk RF, Pasquini MC, Perez WS, Zhang MJ, Krauter J and Antin JH. HLA-identical sibling allogeneic trans-plants versus chemotherapy in AML. Biol. Blood marrow transplant. 2008; 14(2): 187-96.

Schmuck R, Warneke V, Behrens HM, Simon E, Weichert W and Röcken C. Genotypic and phenotypic characterization of side population of gastric cancer cell lines. Am J Pathol. 2011; 178(4): 1792-804.

Schoch C and Haferlach T. Cytogenetics in acute myeloid leukemia. Curr Oncol Rep. 2002; 5: 390.

Schuster R, Max N, Mann B, et al. Quantitative real-time PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers. Int. J. Cancer. 2004; 10: 108(2): 219.

Secker-Walker L. Cytogenetics. In: Hoffbrand A, Lewis S and Tudenham E. (eds). In: Postgraduate Hematology. 4th ed. Oxford, Boston. 1999; 336.

Seigel GM, Hackam AS, Ganguly A, Mandell LM and Fernandez FG. Human embryonic and neuronal stem cell markers in retinoblastoma. Mol Vis. 2007; 13: 823.

Sergey V, Shmelkov L, Clair R, et al. Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood. 2004; 103(6): 2055.

Shimada M, Sugimoto K, Iwahashi S, Utsunomiya T, Morine Y, Imura S and Ikemoto T. CD133 expression is a potential prognostic indicator in intrahepatic

cholangiocarcinoma. *J Gastroenterol*. 2010; 45(8): 896-902.

Shimizu K, Itoh T, Shimizu M, Ku Y and Hori Y. CD133 expression pattern distinguishes intraductal papillary mucinous neoplasms from ductal adenocarcinomas of the pancreas. *Pancreas*. 2009; 38(8): e207-14.

Shmelkov SV, Jun L, St Clair R et al. Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. *Blood*. 2004; 103: 2055.

Smith MT, Zhang L, McHale CM, Skibola CF, Rappaport SM. Benzene, the exposome and future investigations of leukemia etiology. *Chem Biol Interact*. 2011.

Snell V, Jackson D, Buck D, et al. Expression of AC133 antigen in leukemic and normal progenitors. *Blood*. 1998; 92: 119.

Sone M, Itoh H, Yamahara K, et al. Pathway for differentiation of human embryonic stem cells to vascular cell components and their potential for vascular regeneration. *Arterioscler Thromb Vasc Biol*. 2007; 27(10): 2127.

Strauss R, Li ZY, Liu Y, Beyer I, Persson J, Sova P, Möller T, Pesonen S, Hemminki A, Hamerlik P, Drescher C, Urban N, Bartek J and Lieber A. Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. *PLOS One*. 2011 Jan; 6(1): e16186.

Swaminathan SK, Olin MR, Forster CL, Cruz KS, Panyam J and Ohlfest JR. Identification of a novel monoclonal antibody recognizing CD133. *J Immunol Methods*. 2010; 361(1-2): 110-5.

Swirsky DM and Richards SJ. Laboratory diagnosis of acute myeloid leukemia. *Balliere's Clinical Haematol*. 2001; 14(1): 154-55.

Taguchi J, Miyazaki Y, Tsutsumi C, et al. Expression of the myeloperoxidase gene in AC133 positive leukemia cells relates to the prognosis of acute myeloid leukemia. *Leuk Res*. 2006; 30(9): 1105.

Tamai H and Inokuchi K. 11q23/MLL acute leukemia: update of clinical aspects. *J Clin Exp Hematop*. 2010; 50(2): 91-8.

- Tandonnet J, Clavel J, Baruchel A, Nacka F and Perel Y.** Myeloid leukemia in children with Down syndrome: report of the registry-based French experience between 1990 and 2003. *Pediatr Blood Cancer*. 2010; 54(7):927-933.
- Tangen JM, Fløisand Y, Foss-Abrahamsen J, et al.** Survival in adults with acute myelogenous leukemia. *Tidsskr Nor Laegeforen*. 2008; 128(10):1164.
- Theml H, Grosshadern K and Haferlach T.** Abnormalities of the white cell series. In: *Color Atlas of Hematology Practical Microscopic and Clinical Diagnosis*. By: Georg Thieme Verlag (Eds.); Germany; Thieme Medical Publishers. 2004; 92.
- Thomas M, Gebner A, Vornlocher H, et al.** Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells. *Blood*. 2005; 106(10): 3559.
- Tkachuk DC and Hirschmann JV.** Acute leukemias. In: *Wintrobe's atlas of clinical hematology*, By: Tkachuk DC and Hirschmann JV. (eds), (1st Edition). Lippincott Williams & Wilkins publishers. 2007; 102.
- Tong Q, Zheng L, Tang S, Ruan Q, Liu Y, Li S, Jiang G and Cai J.** Expression and clinical significance of stem cell marker CD133 in human neuroblastoma. *World J Pediatr*. 2008; 4 (1): 58-62.
- Tsurumi C, Esser N, Firat E, Gaedicke S, Follo M, Behe M, Elsässer-Beile U, Grosu AL, Graeser R and Niedermann G.** Non-invasive in vivo imaging of tumor-associated CD133/prominin. *PLoS One*. 2010; 5(12): e15605.
- Tsuzuki S and Enver T.** Interactions of GATA-2 with the promyelocytic leukemia zinc finger (PLZF) protein, its homologue FAZF, and the t (11; 17)-generated PLZF-retinoic acid receptor alpha oncoprotein. *Blood*. 2002; 99: 3404.
- Uchida N, Buck DW, He D, et al.** Direct isolation of human central nervous system stem cells. *Proc Natl Acad Sci USA*. 2000; 97: 14720.
- Vardiman JW, Arber DA, Brunning RD, Larson AA, Matutes E, Baumann I and Thiele J.** Therapy-related myeloid neoplasms. In: *WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues*. 4th edition. Swerdlow SH, Campo E, Harris

NL, et al. (eds.). International Agency for Research on Cancer (IARC), Lyon, France, 2008; 127-129.

Vardiman JW, Harris NL and Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. *Blood*. 2002; 100: 2292.

Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A and Bloomfield, CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. *Blood*. 2009; 114(5):937-951.

Vercauteren SM and Sutherland HJ. CD133 (AC133) expression on AML cells and progenitors. *Cytotherapy*. 2001; 3(6): 449.

Wang J, Li F, Zhang G, Chen Y, Hu Y, Chen X, Lu B and Zhang X. Two novel monoclonal antibodies against human CD133-2: distinct epitopes and agonist activity to enhance growth of CD133 expression cells in vitro. *Hybridoma (Larchmt)*. 2010; 29(3): 241-9.

Wang LL, Gao C and Chen BA. Research Progress on Mechanism of MDS Transformation into AML. *Journal of experimental hematology*. 2011; 19(1): 254-259.

Wang W, Wang HY, Zhao HX, Cui ZG and Li GL. Expression of CD133 in bone marrow cells of patients with leukemia and myelodysplastic syndrome. *Journal of experimental hematology*. 2007; 15(3): 470-3.

Wang X, Yao J, Zheng J, Liu J, Lix Q, He Y, Yu J, Yang J, Wei J, Liu Z and Huang S. Immunophenotypes in 115 patients with acute myeloid leukemia by multicolor flow cytometry. *Zhongguo Shi Yan Xue Za Zhi*. 2005a; 13(2): 250.

Weinblatt M. Acute myeloblastic leukemia. e-medicine world Medical library. 2006: 1.

Weir EG and Borowitz MJ. Flow cytometry in the diagnosis of acute leukemia. *Semin Hematol*. 2001; 38: 124.

Wheless JR. Flow instrumentation and data analysis. In: *Diagnostic Flow cytometry*.

By: Coon John S, Weinstein Ronald S, Bailey F and Copenhaver W. (eds); Baltimore; Williams and Wilkins. 1991; 17.

Wiernik PH. Extramedullary manifestations of adult leukemia. In: American Cancer Society Atlas of Clinical Oncology Adult Leukemias. By: Steele GD, Phillips TL, Chabner BA and Gansler TS. (Eds.), 4th edition; London; Cambridge University Press. 2003; 275.

Wierzbowska A, Robak T, Krawczyńska A, et al. Kinetics and apoptotic profile of circulating endothelial cells as prognostic factors for induction treatment failure in newly diagnosed acute myeloid leukemia patients. *Ann Hematol.* 2008; 87(2): 97.

Wu JT. Quantitative immunoassay: A practical guide for assay establishment, troubleshooting, and clinical application. Washington D.D. APCC Press. 2000; 88-95.

Wuchter C, Ratel R, Spahn G, Schoch C and Harbott J. Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping. *Hematologica.* 2001; 86-154.

Xuereb J and Blundell R. Acute leukaemia. *International Journal of Molecular Medicine and Advance Sciences.* 2007; 3(4): 138-144.

Yamashita Y, Ohashi J, Hirai Y and Mano H. Gene expression profiles of CD133 positive fractions predict the survival of individuals with acute myeloid leukemia. *Cancer Genomics and Proteomics.* 2006; 3(3): 169.

Yang C, Ynag Y, Gupta N, Liu X, He A , Liu L, Zuok J, Chang Y and Fang F. Pentaspan membrane glycoprotein, Prominin-1, is involved in glucose metabolism and cytoskeleton alteration. *Biochemistry (Moscow).* 2007; 72(8): 854-862.

Yin S, Hu C, Chen X, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. *Int J Cancer.* 2007; 120(7): 1444.

Yu Y, Flint A, Evan L, et al. AC133-2, a novel isoform of human AC133 stem cell antigen. *J. Biol. Chem.* 2002; 277(23): 20711.

Zheng J, Wang X, Hu Y, et al. An association study of immunophenotypic, cytogenetic,

and clinical features of 180 AML patients in China. *Cytometry B Clin Cytom.* 2007; 74B(1): 25.

Zhou L, Wei X, Cheng L, et al. CD133, one of the markers of cancer stem cells in Hep-2 cell line. *The New England Journal of Medicine.* 2007; 117: 455.

Zhou M, Gu L, Abshine TC, et al. Incidence and prognostic significance of oncoprotein over expression in childhood ALL. *Leukemia.* 2000; 14: 61.

Zhou Y, Li Q, Meng HX, et al. The expression and clinical significance of early differentiation antigens in acute leukemia. *Zhonghua Nei Ke Za Zhi.* 2005; 44(1): 46.

Zhou Y, Meng HX, Yu Z, Li Q, Wang YF, Mai YJ, Han JL and Qiu LG. The expression of CD133 in acute leukemia and its clinical significance. *Zhonghua Xue Ye Xue Za Zhi.* 2004; 25 (7): 401- 404.

(<http://www.biology.iupui.edu/biocourses/n100/images/11translocation.gif>, 8/2010)

([http://www.Goldman Cecil Medicine on MD Consult 1.htm](http://www.GoldmanCecilMedicine.com/MDConsult1.htm), 8/2010).